Short answer
INTEGRA LIFESCIENCES HOLDINGS CORP (IART) filed its Q1 2026 10-Q quarterly report on May 5, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $392M (up 2.4% year over year) with net income of −$5M.
Q1 2026 key financials · XBRL
- Revenue
- $392M
- +2.4% YoY
- Net income
- −$5M
- +81.7% YoY
- Operating margin
- 2.9%
- EPS (diluted)
- −$0.06
- +81.8% YoY
Source: XBRL data from the INTEGRA LIFESCIENCES HOLDINGS CORP (IART) Q1 2026 10-Q on SEC EDGAR. USD.
INTEGRA LIFESCIENCES HOLDINGS CORP Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Net loss $(4.6)M vs $(25.3)M YoY, or $(0.06) vs $(0.33) diluted share
- Special charges $26.7M vs $42.6M YoY, including structural optimization charges of $9.3M
- Boston recall and Braintree transition charges $7.7M vs $14.8M YoY
- Restructuring expenses $3.8M in Q1 2026, within approximately $12.3M expected through 2026
- Near-term headwinds: FDA quality remediation, CMP execution, tariffs, supply disruptions, and geopolitical uncertainty
Risk Factors
- No material risk-factor changes from the December 31, 2025 Form 10-K
- No newly added risk factor or triggering event disclosed this quarter
- Regulatory, legal, and compliance risks remain those identified in the 2025 Form 10-K
- Operational, competitive, market, and financial risks remain unchanged from the 2025 Form 10-K
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other INTEGRA LIFESCIENCES HOLDINGS CORP quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.